KBC Group
IPXL

KBC Group’s Impax Laboratories, Inc. IPXL Stock Holding History

KBC Group’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-656
Closed -$9K – 1351
2016
Q4 		$9K Sell
656
-5,282
-89% -$90.3K ﹤0.01% 1303
2016
Q3 		$141K Buy
5,938
+4,909
+477% +$132K ﹤0.01% 1197
2016
Q2 		$30K Sell
1,029
-3,520
-77% -$115K ﹤0.01% 1245
2016
Q1 		$146K Sell
4,549
-10,692
-70% -$376K ﹤0.01% 1072
2015
Q4 		$652K Sell
15,241
-18,475
-55% -$738K 0.01% 728
2015
Q3 		$1.19M Sell
33,716
-27,706
-45% -$1.25M 0.02% 551
2015
Q2 		$2.82M Buy
61,422
+22,934
+60% +$1.09M 0.04% 450
2015
Q1 		$1.8M Sell
38,488
-42,179
-52% -$1.68M 0.02% 576
2014
Q4 		$2.56M Buy
80,667
+25,879
+47% +$757K 0.03% 523
2014
Q3 		$1.3M Sell
54,788
-4,404
-7% -$113K 0.05% 440
2014
Q2 		$1.77M Buy
+59,192
New +$1.6M 0.02% 626

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

KBC Group's IPXL Position: Q1 2017 in Review

KBC Group sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 656 shares — an estimated $9K sold.

KBC Group first reported a position in IPXL in Q2 2014 and held it in 11 quarters. The position peaked at $2.82M in Q2 2015. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

  • KBC Group reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
  • KBC Group sold 656 Impax Laboratories, Inc. shares in Q1 2017, an estimated $9K.
  • KBC Group first reported a position in Impax Laboratories, Inc. in Q2 2014 and held it in 11 quarters.
  • KBC Group's Impax Laboratories, Inc. position peaked at $2.82M in Q2 2015.
  • 178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on KBC Group's 13F filing for Q1 2017, filed 10 May 2017.